
Guideline Updates G12: Hypertension in 2025: A Universal Target, PREVENT Risk, and Race-Neutral First-Line Therapy
The 2025 AHA/ACC multisociety guideline moves to a universal under 130/80 target, swaps the Pooled Cohort Equations for the PREVENT calculator, removes race from drug selection, and widens primary aldosteronism screening










